Scarica l'app Stockscreener
94.00
1.64%
1.52
Dopo l'orario di chiusura:
94.00
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MIRM Giù?
Forum
Previsione
Precedente Chiudi:
$92.48
Aprire:
$93.34
Volume 24 ore:
621.78K
Relative Volume:
0.78
Capitalizzazione di mercato:
$5.73B
Reddito:
$521.31M
Utile/perdita netta:
$-23.36M
Rapporto P/E:
-196.61
EPS:
-0.4781
Flusso di cassa netto:
$54.87M
1 W Prestazione:
+0.72%
1M Prestazione:
+6.29%
6M Prestazione:
+33.31%
1 anno Prestazione:
+127.55%
Intervallo 1D:
$92.13
$94.67
Intervallo di 1 settimana:
$90.00
$95.61
Portata 52W:
$40.00
$109.28
Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile
Nome
Mirum Pharmaceuticals Inc
Settore
Industria
Telefono
650-667-4085
Indirizzo
989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY
Compare MIRM vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MIRM
Mirum Pharmaceuticals Inc
|
94.00 | 5.64B | 521.31M | -23.36M | 54.87M | -0.4781 |
VRTX
Vertex Pharmaceuticals Inc
|
430.14 | 108.36B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
731.77 | 78.05B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
775.03 | 48.74B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
302.11 | 41.16B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
298.16 | 33.17B | 5.36B | 287.73M | 924.18M | 2.5229 |
Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-18 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-09-24 | Iniziato | TD Cowen | Buy |
| 2025-08-11 | Ripresa | Stifel | Buy |
| 2025-05-19 | Ripresa | H.C. Wainwright | Buy |
| 2024-04-17 | Iniziato | Stifel | Buy |
| 2023-12-18 | Reiterato | H.C. Wainwright | Buy |
| 2023-11-20 | Ripresa | JP Morgan | Overweight |
| 2023-11-13 | Iniziato | Morgan Stanley | Overweight |
| 2023-10-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-10-17 | Ripresa | Evercore ISI | Outperform |
| 2023-09-20 | Iniziato | JMP Securities | Mkt Outperform |
| 2022-09-01 | Iniziato | Citigroup | Buy |
| 2021-09-20 | Iniziato | JP Morgan | Overweight |
| 2020-08-07 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2020-08-03 | Iniziato | H.C. Wainwright | Buy |
| 2020-07-31 | Iniziato | Piper Sandler | Overweight |
| 2020-06-25 | Iniziato | Robert W. Baird | Outperform |
| 2019-08-12 | Iniziato | Citigroup | Buy |
| 2019-08-12 | Iniziato | Evercore ISI | Outperform |
| 2019-08-12 | Iniziato | Guggenheim | Buy |
| 2019-08-12 | Iniziato | ROTH Capital | Buy |
| 2019-08-12 | Iniziato | Raymond James | Outperform |
Mostra tutto
Mirum Pharmaceuticals Inc Borsa (MIRM) Ultime notizie
BlackRock (NASDAQ: MIRM) Holds 3.47M Shares, 5.7% Stake - Stock Titan
Mirum’s brelovitug succeeds in Phase 2b HDV trial - TipRanks
Baird raises Mirum Pharmaceuticals stock price target on HDV data By Investing.com - Investing.com Canada
Mirum Pharmaceuticals Reports Positive Phase 2b Results for Brelovitug in HDV – Key Efficacy and Safety Data Shared, Phase 3 and BLA Timeline Announced - Minichart
Mirum Pharmaceuticals Announces Primary Endpoint Met In Phase 2B Portion Of The Azure-1 Study - TradingView
Mirum’s hepatitis delta drug meets phase 2b study goals - Investing.com
Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 2b Portion of the AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus - The Joplin Globe
Mirum’s hepatitis delta drug meets phase 2b study goals By Investing.com - Investing.com Canada
Brelovitug shows high HDV response rates in Mirum (NASDAQ: MIRM) Phase 2b - Stock Titan
Executive pay, board elections headline Mirum (NASDAQ: MIRM) 2026 proxy - Stock Titan
Will Livmarli Continue to Aid Mirum's Top Line in Q1 Earnings? - qz.com
Trading Systems Reacting to (MIRM) Volatility - Stock Traders Daily
Will Livmarli continue to aid Mirum's top line in Q1 earnings? - MSN
Morgan Stanley Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Maintains Target Price $130 - Moomoo
Citizens Jmp Reiterates Market Outperform Rating for Mirum Pharmaceuticals (NASDAQ:MIRM) - MarketBeat
Mirum Pharmaceuticals (MIRM) Stock: Why It Could Stabilize (Mini Selloff) 2026-04-20Institutional Flow - Cổng thông tin điện tử Tỉnh Sơn La
Mirum Pharmaceuticals 2026 Analysis: Revenue Growth & Pipeline MilestonesNews and Statistics - IndexBox
2 Under-the-Radar Biotech Stocks Worth Buying for the Long Term - AOL.com
Mirum Pharmaceuticals, Inc. (MIRM) Earnings Expected to Grow: What to Know Ahead of Q4 Release - Eastern Progress
Mirum pharmaceuticals director Saira Ramasastry sells $193,800 in stock By Investing.com - Investing.com India
Mirum pharmaceuticals director Saira Ramasastry sells $193,800 in stock - Investing.com
Mirum (MIRM) director uses options, sells 2,000 pre-planned shares - Stock Titan
MIRM (NASDAQ: MIRM) files Rule 144: 2,000 shares via option exercise - Stock Titan
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 13, 2026 - BioSpace
Is It Too Late To Consider Mirum Pharmaceuticals (MIRM) After Its Strong Multi‑Year Share Price Run? - Yahoo Finance
Mirum Pharmaceuticals reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
ETF Watch: What are analysts price targets for Mirum Pharmaceuticals IncMarket Trend Report & Consistent Profit Alerts - baoquankhu1.vn
Aug Movers: Does Mirum Pharmaceuticals Inc stock benefit from AI growthMarket Activity Summary & Stepwise Trade Signal Guides - baoquankhu1.vn
Prediction: Buying This Biotech Stock Today Could Set You Up for Life - Yahoo Finance
Tudor Investment Corp ET AL Takes $2.03 Million Position in Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Cantor Fitzgerald Sticks to Their Buy Rating for Mirum Pharmaceuticals (MIRM) - The Globe and Mail
How Mirum Pharmaceuticals Inc. (MIRM) Affects Rotational Strategy Timing - Stock Traders Daily
Cantor Fitzgerald reiterates Mirum Pharmaceuticals stock rating By Investing.com - Investing.com Canada
Bluejay Therapeutics 2025 Financials: Mirum Pharmaceuticals Merger, Liquidity, and Key Financial Statements - Minichart
Mirum (MIRM) details Bluejay deal and $268.5M PIPE financing - Stock Titan
Primary Sclerosing Cholangitis Market is expected to Hit US$ - openPR.com
18,710 Shares in Mirum Pharmaceuticals, Inc. $MIRM Purchased by SG Americas Securities LLC - MarketBeat
Mirum Pharmaceuticals, Inc. (MIRM) Surpasses Q3 Earnings and Revenue Estimates - MSN
Mirum (MIRM) Q1 2025 Earnings Call Transcript - AOL.com
MIRM Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
MIRM PE Ratio & Valuation, Is MIRM Overvalued - Intellectia AI
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Mirum Pharmaceuticals, Inc. (MIRM) stock price, news, quote and history - Yahoo Finance UK
Why Is Mirum Pharmaceuticals (MIRM) Down 3.6% Since Last Earnings Report? - Eastern Progress
Mirum Pharmaceuticals, Inc. (MIRM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Mirum Pharmaceuticals (MIRM) Moves 5.1% Higher: Will This Strength Last? - qz.com
Mirum Pharmaceuticals (MIRM) Rises 5.1%: Can This Upward Momentum Continue? - Bitget
Mirum Pharma (MIRM) Earnings Call Transcript - AOL.com
JPMorgan Chase & Co. Sells 380,067 Shares of Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
(MIRM) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Mirum Pharmaceuticals Inc Azioni (MIRM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.29%
0.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):